17 pending office actions • 9 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Acceleron Pharma, Inc. | 5 |
| Disc Medicine, Inc. | 3 |
| Transcode Therapeutics, Inc. | 2 |
| Encoded Therapeutics, Inc. | 2 |
| ArmaGen, Inc. | 1 |
| Safe Haven Defense US, LLC | 1 |
| Pharmanest LLC | 1 |
| Xylonix Pte. Ltd. | 1 |
| Neurogastrx, Inc. | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19401802 | Untitled | ArmaGen, Inc. | KIM, YUNSOO | 1641 | Non-Final OA | |
| 18911495 | WINDOW PROTECTION SYSTEM | Safe Haven Defense US, LLC | DICUS, TAMRA | 1787 | Non-Final OA | Oct 10, 2024 |
| 18290403 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | Disc Medicine, Inc. | PATEL, SAGAR S | 1626 | Non-Final OA | Nov 13, 2023 |
| 18376111 | SYSTEMS AND METHODS FOR QUANTITATIVE PHENOTYPING OF BIOLOGICAL FIBRILAR STRUCTURES | Pharmanest LLC | TSAI, TSUNG YIN | 2656 | Non-Final OA | Oct 03, 2023 |
| 18282094 | PHARMACEUTICAL POLYMER CONJUGATES | Xylonix Pte. Ltd. | BAEK, JONGHWAN NMN | 1618 | Non-Final OA | Sep 14, 2023 |
| 18280899 | ACTRII PROTEINS AND USES THEREOF | Acceleron Pharma, Inc. | D' AMBROSIO, THEA | 1654 | Non-Final OA | Sep 07, 2023 |
| 18280837 | COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA | Disc Medicine, Inc. | SHIAO, REI TSANG | 1691 | Non-Final OA | Sep 07, 2023 |
| 18280774 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA ASSOCIATED WITH A RIBOSOMAL DISORDER | Disc Medicine, Inc. | RZECZYCKI, PHILLIP MATTHEW | 1625 | Non-Final OA | Sep 07, 2023 |
| 18271258 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION | Acceleron Pharma, Inc. | BRADLEY, CHRISTINA | 1654 | Non-Final OA | Jul 07, 2023 |
| 18270361 | TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY | Transcode Therapeutics, Inc. | BROWE, DAVID | 1617 | Non-Final OA | Jun 29, 2023 |
| 18215550 | NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY | Transcode Therapeutics, Inc. | CABRAL, ROBERT S | 1614 | Non-Final OA | Jun 28, 2023 |
| 18270001 | METHODS OF METABOLIZING METOPIMAZINE AND ITS SALTS | Neurogastrx, Inc. | KOSTURKO, GEORGE W | 1621 | Non-Final OA | Jun 28, 2023 |
| 18035329 | FORMULATIONS COMPRISING ACTRII POLYPEPTIDE VARIANTS | Acceleron Pharma, Inc. | FISCHER, JOSEPH | 1658 | Non-Final OA | May 04, 2023 |
| 18011261 | ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | Acceleron Pharma, Inc. | MIKNIS, ZACHARY J | 1658 | Final Rejection | Dec 19, 2022 |
| 17602936 | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF THERAPEUTICS | Encoded Therapeutics, Inc. | REGLAS, GILLIAN CHELSEA | 1632 | Non-Final OA | Oct 11, 2021 |
| 17442057 | MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS | Encoded Therapeutics, Inc. | RYAN, DOUGLAS CHARLES | 1635 | Non-Final OA | Sep 22, 2021 |
| 16987756 | METHODS AND COMPOSITIONS FOR TREATING INEFFECTIVE ERYTHROPOIESIS | Acceleron Pharma, Inc. | MIKNIS, ZACHARY J | 1658 | Final Rejection | Aug 07, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial